Literature DB >> 14692715

The role of hepatic Mrp2 in the interaction of flavopiridol and bilirubin: impact on therapy.

W Jäger1, E Gehring, B Hagenauer, S Aust, A Senderowicz, T Thalhammer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14692715     DOI： 10.5414/cpp41610

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN： 0946-1965            Impact factor:   1.366


× No keyword cloud information.
  6 in total

1.  Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias.

Authors:  William Blum; Mitch A Phelps; Rebecca B Klisovic; Darlene M Rozewski; Wenjun Ni; Katie A Albanese; Brad Rovin; Cheryl Kefauver; Steven M Devine; David M Lucas; Amy Johnson; Larry J Schaaf; John C Byrd; Guido Marcucci; Michael R Grever
Journal:  Haematologica       Date:  2010-05-11       Impact factor: 9.941

2.  Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.

Authors:  Mitch A Phelps; Thomas S Lin; Amy J Johnson; Eunju Hurh; Darlene M Rozewski; Katherine L Farley; Di Wu; Kristie A Blum; Beth Fischer; Sarah M Mitchell; Mollie E Moran; Michelle Brooker-McEldowney; Nyla A Heerema; David Jarjoura; Larry J Schaaf; John C Byrd; Michael R Grever; James T Dalton
Journal:  Blood       Date:  2008-11-03       Impact factor: 22.113

3.  Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition.

Authors:  Wenjun Ni; Jia Ji; Zunyan Dai; Audrey Papp; Amy J Johnson; Sunjoo Ahn; Katherine L Farley; Thomas S Lin; James T Dalton; Xiaobai Li; David Jarjoura; John C Byrd; Wolfgang Sadee; Michael R Grever; Mitch A Phelps
Journal:  PLoS One       Date:  2010-11-01       Impact factor: 3.240

Review 4.  A short update on cancer chemoresistance.

Authors:  Gerhard Hamilton; Barbara Rath
Journal:  Wien Med Wochenschr       Date:  2014-09-24

5.  Genotyping panel for assessing response to cancer chemotherapy.

Authors:  Zunyan Dai; Audrey C Papp; Danxin Wang; Heather Hampel; Wolfgang Sadee
Journal:  BMC Med Genomics       Date:  2008-06-11       Impact factor: 3.063

Review 6.  Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics.

Authors:  Kohji Noguchi; Kazuhiro Katayama; Yoshikazu Sugimoto
Journal:  Pharmgenomics Pers Med       Date:  2014-02-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.